Shanghai Medicilon Inc. (688202.SH) plans to repurchase company shares worth 50-100 million yuan.
Medisy (688202.SH) announced that the company plans to use its own funds and repurchase special loans through the Shanghai Securities...
Shanghai Medicilon Inc. (688202.SH) announced that the company plans to use its own funds and special repurchase loans to repurchase some of the company's issued Renminbi ordinary shares (A shares) through the Shanghai Stock Exchange trading system in a centralized competitive bidding manner, and will use the repurchased shares for future equity incentives or employee stock ownership plans or to cancel and reduce the company's registered capital at an appropriate time in the future. The total amount of the repurchase funds shall not be less than RMB 50 million (inclusive) and not more than RMB 100 million (inclusive), and the repurchase price of the shares shall not exceed RMB 54 per share (inclusive). The repurchase period shall be within 6 months from the date of approval of the repurchase plan by the company's shareholders' meeting.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025